{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:03:18Z","timestamp":1781650998657,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clineuro.2023.107885","type":"journal-article","created":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T09:35:56Z","timestamp":1688895356000},"page":"107885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine"],"prefix":"10.1016","volume":"232","author":[{"given":"Jasem","family":"Al-Hashel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar Farouk","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"AlMojel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clineuro.2023.107885_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","article-title":"Specific toxicity of 2- chlorodeoxyadenosine toward resting and proliferating human lymphocytes","volume":"62","author":"Carson","year":"1983","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clineuro.2023.107885_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/14737175.5.6.721","article-title":"Cladribine for multiple sclerosis: review and current status","volume":"5","author":"Sipe","year":"2005","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.clineuro.2023.107885_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41582-019-0268-z","article-title":"Immune reconstitution therapies: concepts for durable remission in multiple sclerosis","volume":"16","author":"Lunemann","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.clineuro.2023.107885_bib4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/jnnp-2017-317411","article-title":"Cladribine: mechanisms and mysteries in multiple sclerosis","volume":"89","author":"Jacobs","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.clineuro.2023.107885_bib5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8914","key":"10.1016\/j.clineuro.2023.107885_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clineuro.2023.107885_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013430","article-title":"Systematic literature review and network meta-analysis in highly active relapsing\u2013remitting multiple sclerosis and rapidly evolving severe multiple sclerosis","volume":"7","author":"Huisman","year":"2017","journal-title":"BMJ Open"},{"issue":"17","key":"10.1016\/j.clineuro.2023.107885_bib8","first-page":"75","article-title":"Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?","volume":"2017","author":"Fernandez","year":"2010","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2023.107885_bib9","doi-asserted-by":"crossref","unstructured":"G. Giovannoni, G. Comi, S. Cook, et al., A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis, N. Engl. J. Med., vol. 362, pp. 416\u201326.","DOI":"10.1056\/NEJMoa0902533"},{"issue":"12","key":"10.1016\/j.clineuro.2023.107885_bib10","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2023.107885_bib11","unstructured":"Merck Serono Europe Limited, MAVENCLAD 10\u2009mg tablets summary of product characteristics, 2017. Cited; Available from. \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004230\/WC500234561\u3009."},{"key":"10.1016\/j.clineuro.2023.107885_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2023.107885_bib13","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.clineuro.2023.107885_bib14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clineuro.2023.107885_bib15","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2023.107885_bib16","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(16)31320-4","article-title":"Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function","volume":"389","author":"Ontaneda","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clineuro.2023.107885_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ana.20740","article-title":"Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients","volume":"59","author":"R\u00edo","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clineuro.2023.107885_bib18","doi-asserted-by":"crossref","unstructured":"G. Giovannoni, G. Comi, K. Rammohan, P. Rieckmann, P. Vermersch, F. Dangond, B. Keller, D. Jack, Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets in the CLARITY and CLARITY extension studies, in: Presented at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting, Oct 15, 2019, p. EP1573.","DOI":"10.1016\/j.jns.2019.10.291"},{"key":"10.1016\/j.clineuro.2023.107885_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jamaneurol.2013.5486","article-title":"Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?","volume":"71","author":"Bevan","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clineuro.2023.107885_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.msard.2011.08.001","article-title":"Disease activity free status in MS","volume":"1","author":"Lublin","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.clineuro.2023.107885_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2023.107885_bib22","unstructured":"N. Publication, National Cancer Institute, Common terminology criteria for adverse events, vol. 4, 2009, #09-7473."},{"key":"10.1016\/j.clineuro.2023.107885_bib23","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"12","author":"Pfeuffer","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.clineuro.2023.107885_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.msard.2019.04.033","article-title":"The prevalence of multiple sclerosis continues to increase in Kuwait","volume":"32","author":"Alroughani","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2023.107885_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2023.107885_bib26","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000477","article-title":"Cladribine tablets added to IFN-\u03b2 in active relapsing MS. The ONWARD study","volume":"5","author":"Montalban","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"11","key":"10.1016\/j.clineuro.2023.107885_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fneur.2020.00489","article-title":"Single-center 8-years clinical follow-up of cladribine-treated patients from phase 2 and 3 trials","volume":"17","author":"Moccia","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.clineuro.2023.107885_bib28","first-page":"310","article-title":"Long-term lymphocyte counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5\u2009mg\/kg: total lymphocytes, B and T cell subsets","volume":"23","author":"Soelberg-Sorensen","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2023.107885_bib29","first-page":"317","article-title":"Rates of lymphopenia year-by-year in patients with relapsing multiple sclerosis treated and retreated with cladribine tablets 3.5\u2009mg\/kg","volume":"23","author":"Cook","year":"2017","journal-title":"Mult. Scler. J."},{"issue":"1\u201311","key":"10.1016\/j.clineuro.2023.107885_bib30","first-page":"53365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing\u2013remitting multiple sclerosis: the CLARITY extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846723003013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846723003013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:45:29Z","timestamp":1759589129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846723003013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":30,"alternative-id":["S0303846723003013"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2023.107885","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2023.107885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107885"}}